drugset / Trial / NCT00813384
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
Timeline
- Start
- 2008-12
- Primary completion
- 2013-02
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 208 | Small molecule | 25 mg | Oral |
| Subject | AMG 208 | Small molecule | 50 mg | Oral |
| Subject | AMG 208 | Small molecule | 100 mg | Oral |
| Subject | AMG 208 | Small molecule | 150 mg | Oral |
| Subject | AMG 208 | Small molecule | 200 mg | Oral |
| Subject | AMG 208 | Small molecule | 300 mg | Oral |
| Subject | AMG 208 | Small molecule | 400 mg | Oral |